Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma
Phase 2
Withdrawn
- Conditions
- Recurrent Glioblastoma
- Interventions
- Device: Exablate MRgFUS + neoadjuvant pembolizumab
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT05879120
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT05879146
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Accelerated Recovery After MIS Hepatectomy (ARAMIS Hep) to Support Early Discharge for Patients Undergoing Minimally Invasive Liver Resection
Not Applicable
Recruiting
- Conditions
- Liver
- Interventions
- Behavioral: Questionnaires
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT05879159
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
Phase 2
Not yet recruiting
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05873192
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection
Phase 1
Suspended
- Conditions
- Pancreatic Cyst
- Interventions
- Drug: Hyperpolarized 13-C-pyruvate
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT05873699
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging
Phase 1
Suspended
- Conditions
- Ovarian Cancer
- Interventions
- Drug: Hyperpolarized 13-C-pyruvate
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05866679
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations
Phase 1
Withdrawn
- Conditions
- Lung CancerGastro-intestinal Cancer
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05848843
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck
Early Phase 1
Not yet recruiting
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Drug: Control Group
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT05845307
- Locations
- 🇺🇸
M D Anderson Cancer Centerl, Houston, Texas, United States
Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance
Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- Other: Active Surveillance
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT05840484
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Assessment of Patient Experience and Needs for Patients Undergoing Invasive Inguinal Lymph Node Procedures for Penile Cancer
Recruiting
- Conditions
- Penile Cancer
- Interventions
- Behavioral: Quality of Life QuestionnairesBehavioral: Patient Educational NeedsBehavioral: Symptom Management
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05842031
- Locations
- 🇺🇸
MD Anderson, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath